List of Excipients in Branded Drug BUPIVACAINE HCI

« Back to Dashboard

Generic Drugs Containing BUPIVACAINE HCI

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	METHYLPARABEN
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA HealthFirst	bupivacaine hci	51662-1581	WATER

What are the Most Frequently-Used Excipients in BUPIVACAINE HCI?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	METHYLPARABEN
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Bupivacaine HCl Excipient Strategy and Commercial Opportunities

Last updated: October 27, 2026

Bupivacaine hydrochloride is a mature, commoditized local anesthetic with limited composition-of-matter protection. Commercial differentiation depends on excipient control, preservative-free packaging, route-specific presentations, supply reliability, and workflow advantages rather than on the active ingredient itself. The highest-value opportunities are ready-to-use sterile formats, hyperbaric spinal products, preservative-free multidose alternatives, hospital safety packaging, and differentiated combinations with epinephrine or other compatible agents.

What is the regulatory and commercial status of bupivacaine HCl?

Bupivacaine HCl is an FDA-approved amide local anesthetic used for local infiltration, peripheral nerve block, epidural anesthesia, and spinal anesthesia in selected presentations. It is marketed in multiple strengths, including 0.25%, 0.5%, and 0.75%, generally corresponding to 2.5 mg/mL, 5 mg/mL, and 7.5 mg/mL bupivacaine HCl, respectively [1-4].

Product category	Typical concentration	Primary use	Excipient strategy
Preservative-free injection	0.25%, 0.5%, 0.75%	Infiltration, nerve block, epidural use	Sodium chloride, water for injection, pH adjustment
Multidose injection	0.25%, 0.5%, 0.75%	Institutional procedural use	May contain antimicrobial preservative such as methylparaben
Bupivacaine with epinephrine	Commonly 0.25% and 0.5%	Longer local effect and reduced systemic absorption	Antioxidant system, commonly sodium metabisulfite, plus pH control
Hyperbaric spinal injection	Commonly 0.75%	Intrathecal anesthesia	Dextrose to increase density relative to cerebrospinal fluid
Liposomal bupivacaine	Separate extended-release product	Postsurgical local analgesia	Phospholipid-based multivesicular liposome system

Bupivacaine HCl products are small-molecule injectable drugs, not biologics. Biosimilar regulation does not apply. Generic competition is established, and the main regulatory pathways are abbreviated new drug applications, 505(b)(2) applications for differentiated formulations, and conventional new drug applications for novel delivery systems.

Which excipients are used in bupivacaine HCl injection?

The core formulation is intentionally simple. Typical immediate-release bupivacaine HCl injections contain bupivacaine hydrochloride, sodium chloride, water for injection, and small quantities of hydrochloric acid or sodium hydroxide for pH adjustment [1-4].

Sodium chloride and tonicity control

Sodium chloride is used to adjust osmolality in standard injectable presentations. The target is generally near physiological tonicity, although exact osmolality depends on drug concentration, pH, container, and whether the formulation is intended for epidural, infiltration, or other administration.

A product designed for intrathecal use requires tighter control of osmolality and density. Excessive tonicity can increase injection-site discomfort and may alter neuraxial drug distribution. For a hyperbaric spinal product, the formulation deliberately departs from isotonicity through the addition of dextrose.

Dextrose for hyperbaric spinal formulations

Bupivacaine HCl in dextrose is a distinct formulation strategy. Dextrose increases solution density relative to cerebrospinal fluid, allowing the anesthesiologist to influence intrathecal spread through patient positioning and injection technique [3].

This creates a route-specific commercial opportunity because the excipient is functional rather than merely a processing aid. The product must maintain:

• Stable density across the labeled shelf life
• Consistent bupivacaine concentration
• Low particulate burden
• Suitable pH and osmolality
• Reliable performance in small-volume spinal syringes

A hyperbaric formulation should not be treated as a simple concentration extension of standard bupivacaine injection. It has different clinical handling, packaging, and quality-control requirements.

Preservatives

Multidose bupivacaine HCl presentations may contain an antimicrobial preservative, commonly methylparaben, depending on the manufacturer and container configuration [1,2]. Preservatives can support repeated withdrawals from a multidose vial but create limitations for neuraxial use.

Preservative-free products are commercially important because epidural and intrathecal procedures generally favor formulations without antimicrobial preservatives. A manufacturer can therefore create separate products with the same active ingredient and concentration but different commercial positioning:

1. Preservative-free single-dose vial for neuraxial and broad procedural use.
2. Preserved multidose vial for institutional efficiency.
3. Preservative-free ready-to-administer syringe for operating-room workflow.

The distinction must be explicit in labeling, packaging, storage, and hospital formularies.

Epinephrine and antioxidant systems

Bupivacaine with epinephrine requires an antioxidant because epinephrine is susceptible to oxidation. Sodium metabisulfite is commonly used in epinephrine-containing injectable products [2,4]. The formulation must balance antioxidant protection against sulfite sensitivity and compatibility requirements.

Epinephrine-containing bupivacaine can be positioned for applications where vasoconstriction is clinically useful, including prolonged local effect and reduced systemic uptake. The product is not interchangeable with plain bupivacaine in all clinical settings because epinephrine changes pharmacology, contraindications, monitoring requirements, and patient selection.

What excipient strategy offers the strongest commercial opportunity?

The strongest strategy is differentiated presentation rather than an aggressive new-excipient formulation.

Preservative-free ready-to-use syringes

A prefilled syringe can reduce vial manipulation, preparation time, medication errors, and waste. The main development barriers are:

• Sterile manufacturing and aseptic filling
• Syringe-material compatibility
• Extractables and leachables
• Bupivacaine adsorption or precipitation
• Container closure integrity
• Long-term stability
• Needle and luer compatibility
• Human-factors validation

A ready-to-use format may command a price premium over bulk vials if it reduces pharmacy preparation and operating-room labor. The commercial case is strongest for emergency departments, ambulatory surgery centers, dental surgery, regional anesthesia services, and procedural clinics.

Low-volume, high-concentration formats

A 0.75% formulation can reduce injection volume where clinically appropriate, but high concentration increases the importance of dose calculation and administration controls. A commercial product should use prominent concentration labeling, differentiated vial caps, barcoding, and dose-volume guidance.

The opportunity is operational rather than pharmacological. Hospitals may value smaller packaging and reduced preparation time, but medication-error risk can offset the benefit if multiple strengths use similar labels or containers.

Hyperbaric spinal products

Bupivacaine in dextrose has a defined clinical role and can support a separate product franchise. Commercial differentiation may come from:

• Small-volume single-dose ampoules
• Prefilled spinal syringes
• Clear hyperbaric labeling
• Needle-free transfer systems
• Low-dead-space packaging
• Enhanced carton and barcode controls

The formulation should avoid unnecessary excipients. Every additional component increases the burden for intrathecal safety assessment.

Epinephrine-containing products

Plain bupivacaine and bupivacaine with epinephrine can be sold as complementary products. The opportunity is strongest where clinicians want a longer local effect or a marker of inadvertent intravascular injection.

The excipient system should preserve epinephrine potency throughout shelf life without creating unacceptable discoloration, particulate formation, or container interaction. Sodium metabisulfite content and sulfite labeling must be managed carefully.

What formulation patents protect bupivacaine products?

The original bupivacaine molecule and conventional bupivacaine HCl injection technology are mature. Commercial barriers generally arise from formulation, packaging, manufacturing, and regulatory execution rather than from basic composition-of-matter patents.

Immediate-release bupivacaine HCl

Standard bupivacaine HCl solutions are vulnerable to generic substitution because:

• The active ingredient is well established.
• The formulation uses conventional injectable excipients.
• Multiple manufacturers produce comparable strengths.
• Clinical use is supported by longstanding labeling and practice.
• The product is generally suitable for ANDA-based competition when bioequivalence and pharmaceutical equivalence requirements are met.

A new entrant should not expect durable exclusivity from a conventional sodium chloride and water formulation alone.

Liposomal bupivacaine

Liposomal bupivacaine is a different technology from immediate-release bupivacaine HCl. Exparel uses a multivesicular liposome delivery system and has a formulation based on phospholipids, cholesterol, triglycerides, and other components associated with the DepoFoam platform [5,6].

The liposomal product has a separate patent and regulatory history. Its formulation, manufacturing process, particle characteristics, release profile, and clinical labeling create a higher entry barrier than standard bupivacaine injection. A conventional bupivacaine HCl product does not automatically compete as an equivalent substitute for liposomal bupivacaine.

When does bupivacaine HCl lose exclusivity?

Bupivacaine HCl has already lost practical market exclusivity in the United States. Standard injectable presentations are supplied by multiple generic manufacturers, and the commercial market is driven by price, availability, quality history, and institutional contracting.

The relevant exclusivity questions are therefore product-specific:

Protection or exclusivity type	Relevance to standard bupivacaine HCl
Original active-ingredient patent	Expired
Conventional injectable formulation	Generally open to generic competition
Pediatric exclusivity	Not a current commercial barrier for ordinary products
Orphan exclusivity	Not applicable to standard bupivacaine HCl
Biosimilar exclusivity	Not applicable
Device or prefilled-syringe patents	Potentially relevant to a specific presentation
Novel extended-release formulation patents	Potentially relevant, especially for liposomal or depot products
Manufacturing-process patents	May affect cost or supply, but usually do not block all generic entry

The Orange Book remains the principal U.S. reference for listed patents and exclusivity associated with FDA-approved drug products [7]. Patent conclusions must be made at the specific product and dosage-form level because standard bupivacaine HCl, hyperbaric bupivacaine, epinephrine combinations, and liposomal bupivacaine occupy different regulatory categories.

Are Paragraph IV challenges relevant to bupivacaine HCl?

Paragraph IV litigation is a limited strategic issue for ordinary bupivacaine HCl because the basic product is already generic. It becomes more relevant when a company develops:

• A novel prefilled syringe
• A protected container closure
• A new excipient combination
• A long-acting formulation
• A differentiated method of use
• A liposomal or depot delivery system

For a conventional ANDA, the principal risks are manufacturing approval, drug shortage exposure, facility inspection findings, stability failures, and market-price erosion. For a 505(b)(2) product, patent certification and potential litigation may become material if the reference product has listed patents.

What manufacturing and intellectual-property barriers affect market entry?

The technical barriers are higher than the apparent simplicity of the formulation suggests.

Sterile injectable manufacturing

A supplier must demonstrate control of:

• Bioburden and endotoxin
• Sterility assurance
• Particulate matter
• Visible particles and discoloration
• Fill-volume accuracy
• Container closure integrity
• pH and osmolality
• Assay and related substances
• Stability under labeled storage conditions

Glass vials, polymer syringes, ampoules, and bags can produce different extractables and adsorption profiles. A manufacturer changing the container may need substantial comparability work.

Supply-chain resilience

Bupivacaine HCl is exposed to hospital purchasing cycles and periodic injectable shortages. Commercial value can come from dependable supply, dual-source raw materials, redundant fill-finish capacity, and smaller customer-specific packaging runs.

A low-cost product with unreliable availability may lose contracts to a higher-priced supplier with consistent delivery.

Compatibility and admixture restrictions

Bupivacaine solutions can precipitate or become unstable when mixed with incompatible alkaline or drug solutions. Product labeling should provide clear handling instructions and discourage unvalidated admixture practices [1-4].

Compatibility data can support a commercial differentiator if the product is supplied in a standardized kit or workflow that includes compatible diluents and administration components.

How does bupivacaine HCl compare with liposomal bupivacaine?

Attribute	Immediate-release bupivacaine HCl	Liposomal bupivacaine
Delivery system	Aqueous solution	Multivesicular liposome suspension
Generic competition	Extensive	More limited and technology-dependent
Excipient complexity	Low	High
Manufacturing difficulty	Conventional sterile injectable	Specialized particle and liposome manufacturing
Primary value proposition	Low cost and established use	Extended local analgesia
Patent exposure	Limited for basic product	Greater formulation and process exposure
Pricing	Commodity-oriented	Premium-oriented
Regulatory pathway	Usually ANDA for equivalent products	More complex product-specific pathway

The two products should not be treated as interchangeable commercial categories. Immediate-release bupivacaine HCl competes on cost, availability, and procedural utility. Liposomal bupivacaine competes on duration, clinical positioning, and delivery technology.

What licensing opportunities exist for bupivacaine HCl?

Licensing opportunities are more attractive in delivery technology than in the base molecule. Relevant targets include:

• Prefilled syringe platforms
• Sterile fill-finish partnerships
• Liposome or depot delivery systems
• Regional anesthesia procedure kits
• Hospital barcode and medication-management systems
• Contract manufacturing for preservative-free products
• Geographic distribution rights
• Combination products with compatible adjuncts

The commercial value of a licensing deal depends on whether the partner controls a protected technology, has FDA-approved manufacturing capacity, or owns established hospital contracts. A license covering only conventional bupivacaine HCl composition is unlikely to create durable differentiation.

What generic launch scenarios exist for bupivacaine HCl?

Three launch scenarios are commercially realistic.

Low-cost conventional generic

This strategy targets hospital tenders and group purchasing organizations. Success depends on manufacturing scale, supply reliability, and an efficient cost structure. Margins are likely to compress rapidly if several suppliers compete for the same strength.

Premium preservative-free presentation

A supplier can charge more for a ready-to-use, clearly differentiated preservative-free product with strong packaging and operating-room workflow benefits. The product must demonstrate practical value beyond the label claim.

Specialized spinal or procedural franchise

A company can build a portfolio around hyperbaric bupivacaine, epinephrine-containing bupivacaine, and preservative-free standard injections. This approach increases manufacturing and inventory complexity but can improve contracting leverage and customer retention.

Key Takeaways

• Bupivacaine HCl is a mature generic injectable with no meaningful basic-molecule exclusivity.
• The core excipient system is simple: water for injection, sodium chloride, and pH adjusters.
• Preservative-free packaging is commercially important for epidural and intrathecal use.
• Dextrose creates the functional excipient basis for hyperbaric spinal bupivacaine.
• Epinephrine-containing products require antioxidant protection and separate clinical positioning.
• Prefilled syringes, low-volume formats, spinal presentations, and reliable supply offer the strongest commercial opportunities.
• Conventional bupivacaine HCl is unlikely to support durable premium pricing without packaging, workflow, or delivery differentiation.
• Liposomal bupivacaine is a separate high-complexity product category with distinct formulation, manufacturing, regulatory, and patent considerations.
• Biosimilar competition does not apply.
• Paragraph IV risk is limited for ordinary generic bupivacaine HCl but can become relevant for novel formulations and delivery systems.

FAQs About Bupivacaine HCl Excipient Strategy

Can methylparaben be used in intrathecal bupivacaine?

Intrathecal products are generally positioned as preservative-free. A formulation containing methylparaben would face significant route-specific regulatory and clinical acceptability issues.

Why is dextrose added to spinal bupivacaine?

Dextrose increases solution density, making the formulation hyperbaric relative to cerebrospinal fluid and influencing intrathecal spread.

Is sodium metabisulfite required in plain bupivacaine HCl?

No. Sodium metabisulfite is associated primarily with epinephrine-containing formulations, where it helps limit oxidation of epinephrine.

Can a new excipient create patent protection for bupivacaine HCl?

A new excipient alone rarely creates durable protection. Patent strength depends on a non-obvious formulation, measurable technical benefit, enforceable claims, and regulatory differentiation.

Is liposomal bupivacaine a generic version of bupivacaine HCl injection?

No. Liposomal bupivacaine uses a distinct delivery system and is not equivalent to a conventional aqueous bupivacaine HCl injection.

References

1. DailyMed. (n.d.). Bupivacaine hydrochloride injection prescribing information. U.S. National Library of Medicine.

2. Pfizer Inc. (n.d.). Marcaine and Marcaine with epinephrine prescribing information. U.S. Food and Drug Administration.

3. Pfizer Inc. (n.d.). Marcaine spinal prescribing information. U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (n.d.). Bupivacaine hydrochloride injection drug labeling. FDA.

5. Pacira Pharmaceuticals, Inc. (n.d.). Exparel prescribing information. U.S. Food and Drug Administration.

6. U.S. Patent and Trademark Office. (n.d.). Patent records relating to multivesicular liposome delivery systems. USPTO.

7. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.